Medical devices; exemptions from premarket notification; class II devices--FDA, Final rule
Related Experiment Video
Updated: Oct 23, 2026

Blood Flow Imaging with Ultrafast Doppler
Published on: October 14, 2020
Abstract:
The Food and Drug Administration (FDA) is codifying the exemption from premarket notification of all 62 class II (special controls) devices listed as exempt in a January 21, 1998, Federal Register notice, subject to the limitations on exemptions. FDA has determined that for these exempted devices, manufacturers' submissions of premarket notifications are unnecessary to provide a reasonable assurance of safety and effectiveness. These devices will remain subject to current good manufacturing practice (CGMP) regulations and other general controls. This rulemaking implements new authorities delegated to FDA under the Food and Drug Administration Modernization Act (FDAMA).
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Products: Biologics, Biosimilars and Interchangeables
Good Manufacturing Practices
Drug Classes and Categories
Bioequivalence studies: Biowaivers

